Efficacy of Nivolumab in Patients With Melanoma

Paolo A. Ascierto, MD, National Tumour Institute “Fondazione G. Pascale,” Unit of Melanoma in Naples, Italy, discusses the promising results for nivolumab (Opdivo) in patients with melanoma. 

Paolo A. Ascierto, MD, National Tumour Institute “Fondazione G. Pascale,” Unit of Melanoma in Naples, Italy, discusses the promising results for nivolumab (Opdivo) in patients with melanoma.

According to Ascierto, this agent has proven to be safe and efficacious in this patient population. The incidence of grade 3/4 adverse events (AEs) is also low.